Studies in mice by researchers in Finland, Sweden, and Switzerland have shown how the most aggressive form of brain cancer, glioblastoma, can be stopped in its tracks by an antihistamine drug that triggers a form of cell death caused by leaky lysosomes. An association between the fatty acid binding protein mammary-derived growth inhibitor (MDGI) and poorer prognosis in patients.